Abstract:Background Inactivating alterations in SPOP frequently occur in prostate cancer and promote increased dependency on androgen receptor (AR)‐mediated oncogenic signaling. The presence of SPOP mutation (SPOP‐mutant [SPOP‐mut]) may therefore impact therapeutic outcomes with AR‐directed therapies and docetaxel in metastatic castration‐resistant (mCRPC). Methods This was a retrospective study of mCRPC patients treated at an urban academic hospital (n = 103). Patients underwent tumor DNA sequencing to determine SPOP mutational status (SPOP‐mut). Outcomes measured were overall survival (OS) from diagnosis and treatment with second‐generation AR signaling inhibitor (ARSI) or docetaxel and time to PSA progression (prostate‐specific antigen‐progression‐free survival [PSA‐PFS]) compared by SPOP status using Kaplan–Meier curves and log‐rank test. The univariable and multivariable Cox proportional hazard model evaluated the association of SPOP mutation and outcomes adjusted for clinicopathologic features. Results SPOP‐mut was associated with longer PSA‐PFS in mCRPC (median 1.79 vs. 0.84 years; p = 0.06) and multivariate analysis (hazard ratio [HR] = 0.37; 95% confidence interval [CI]: 0.17–0.84; p = 0.02). SPOP‐mut demonstrated a higher median PSA decline compared to SPOP wild‐type (median decline 100% vs. 92%, p = 0.02). SPOP‐mut was not associated with OS from the start of ARSI or docetaxel (median OS not reached vs. 2.0 years) or PSA‐PFS on docetaxel (median PSA‐PFS 0.4 vs. 0.5 years) in mCRPC. The majority of SPOP mutations were identified in African American (AA) patients (69.2%) compared to Caucasian patients (30.8%). Race‐associated multivariate analysis revealed no significant differences in OS from the start of ARSI or the start of docetaxel and no differences in ARSI or docetaxel PSA‐PFS between AA and Caucasian patients. Molecular profiling demonstrated that AA patients had a higher frequency of SPOP mutations and greater heterogeneity of SPOP variants within the coding sequence. Analysis of concurrent genomic alterations revealed that SPOP mutations co‐occur with APC mutations (p = 0.001) and alterations in the Wnt pathway (p = 0.017). Conclusions Inactivating mutations in SPOP are associated with better response to ARSI treatment in mCRPC overall. Additional analysis with a larger cohort is needed to evaluate the association of SPOP status and outcomes with docetaxel. Race‐associated clinical outcomes and molecular features were observed, suggesting the benefit of biomarker‐directed therapy selection for individualized patient subsets in guiding treatment decisions for mCRPC patients.

Prostate Cancer-associated SPOP Mutations Enhance Cancer Cell Survival and Docetaxel Resistance by Upregulating Caprin1-dependent Stress Granule Assembly.

TGF- signaling regulates <i>SPOP</i> expression and promotes prostate cancer cell stemness

Prostate Cancer-Associated Mutation in SPOP Impairs Its Ability to Target Cdc20 for Poly-Ubiquitination and Degradation.

SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.

SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer

Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP–HIPK2 axis

Identification of SPOP Related Metabolic Pathways in Prostate Cancer.

SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression

SPOP Inhibits BRAF-dependent Tumorigenesis Through Promoting Non-Degradative Ubiquitination of BRAF

Destruction of DDIT3/CHOP Protein by Wild-Type SPOP but Not Prostate Cancer-Associated Mutants

TGF-β signaling regulates SPOP expression and promotes prostate cancer cell stemness

Key pathways in prostate cancer with SPOP mutation identified by bioinformatic analysis

Enhanced autophagy and NFE2L2/NRF2 pathway activation in SPOP mutation-driven prostate cancer

Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover

SPOP mutation induces DNA methylation via stabilizing GLP/G9a

Mutated SPOP E3 Ligase Promotes 17βhsd4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.

Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4

Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer

Molecular features and race‐associated outcomes of SPOP‐mutant metastatic castration‐resistant prostate cancer

SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway

The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) consortium.